Details

Autor(en) / Beteiligte

• Szafir, Deborah
• Lelouët, Hervé
• Imbs, Jean-Louis
• Barouki, R.
• Blayac, J.P.
• Bons, B.
• Caron, J.
• Castot, A.
• Childs, M.
• Daurat, V.
• Deligne, J.
• Delmas, C.
• Demarez, J.P.
• Eschwege, E.
• Garcia-Gibot, A.
• Girard, F.
• Guilhot, J.
• Kreft-Jaïs, C.
• Lagier, G.
• Lamarque, V.
• Lebrun-Vignes, B.
• Lelouet, A.
• Maillère, P.
• Malvy, J.L.
• Mazraani, M.
• Moachon-Chauvelot, L.
• Muzard, D.
• Olivier, P.
• Pappo, M.
• Pastor, E.
• Riché, C.
• Sallière, D.
• Thomas, L.

Titel

Prevention of Drug-Induced Risks

Ist Teil von

• Therapie, 2003-05, Vol.58 (3), p.225-227

Ort / Verlag

Elsevier Masson SAS

Erscheinungsjahr

2003

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Effective prevention of drug-induced risks depends on an accurate understanding of their triggering or predisposing factors, and the quality of information on these available to prescribing practitioners and users. All preclinical and clinical data available on the proprietary medicinal product concerned should facilitate identification of a risk, and these data should be compared with existing data on drugs sharing the same mode of action or therapeutic strategy. This information should be based on a communication plan adapted to the context of the disease under treatment, the therapeutic alternatives available and the benefits expected.